January 11, 2016

, (GLOBE NEWSWIRE) -- (Nasdaq:RPRX) today announced that the summarily affirmed the ruling of the in favor of the Company in the Company's motions for summary judgment that failed to present sufficient evidence to be added as a co-inventor of Patent Nos. 7,737,185 and 7,759,360, covering therapeutic uses of enclomiphene, and that equitable estoppel barred counterclaims seeking to be added as a co-inventor of the patents at issue, in its lawsuit against Dr. .

About Repros Therapeutics Inc.®

focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

For more information, please visit the Company's website at http://www.reprosrx.com. 


CONTACT:



Investor Relations:



(646) 378-2931

thoffmann@troutgroup.com

Source:

News Provided by Acquire Media

Close window | Back to top

Repros Therapeutics Inc. issued this content on 2016-01-11 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-11 14:33:18 UTC

Original Document: http://ir.reprosrx.com/releasedetail.cfm?ReleaseID=949760